The evidence base and existing literature suggest that upregulation of fractalkine/CX3CR1, together with CMV seropositivity and consequent migration of immune and inflammatory cells, is associated with worse outcomes in patients with inflammatory conditions including dilated cardiomyopathy. This evidence concerns the gene CX3CL1 and dilated cardiomyopathy.